{"id":"azopt-1","safety":{"commonSideEffects":[{"rate":null,"effect":"Blurred vision"},{"rate":null,"effect":"Ocular discomfort"},{"rate":null,"effect":"Taste perversion"},{"rate":null,"effect":"Conjunctivitis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Brinzolamide, the active ingredient in Azopt, inhibits carbonic anhydrase II in the ciliary body of the eye, which reduces the secretion of aqueous humor and thereby lowers intraocular pressure. This mechanism makes it effective for treating glaucoma and ocular hypertension by reducing fluid production rather than increasing fluid drainage.","oneSentence":"Azopt is a topical carbonic anhydrase inhibitor that reduces intraocular pressure by decreasing aqueous humor production in the eye.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:03:28.462Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Glaucoma"},{"name":"Ocular hypertension"}]},"trialDetails":[{"nctId":"NCT02390284","phase":"PHASE3","title":"Stop Retinal Ganglion Cell Dysfunction Study","status":"TERMINATED","sponsor":"University of Miami","startDate":"2015-09","conditions":"Glaucoma","enrollment":28},{"nctId":"NCT06883123","phase":"PHASE4","title":"Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost","status":"RECRUITING","sponsor":"Prairie Eye Center","startDate":"2025-05-14","conditions":"Open Angle Glaucoma","enrollment":70},{"nctId":"NCT04944290","phase":"PHASE3","title":"To Compare the Efficacy and Safety of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes","status":"COMPLETED","sponsor":"Padagis LLC","startDate":"2021-05-28","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":447},{"nctId":"NCT05022004","phase":"PHASE3","title":"A Therapeutic Equivalence Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries Limited","startDate":"2021-12-20","conditions":"Primary Open Angle Glaucoma, Ocular Hypertension","enrollment":599},{"nctId":"NCT01722604","phase":"PHASE3","title":"Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2012-01","conditions":"Glaucoma, Open Angle or Ocular Hypertension","enrollment":258},{"nctId":"NCT03896633","phase":"PHASE1, PHASE2","title":"Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2018-02-28","conditions":"Glaucoma, Open Angle or Ocular Hypertension","enrollment":637},{"nctId":"NCT04024072","phase":"PHASE3","title":"To Compare the Safety and Efficacy of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes","status":"COMPLETED","sponsor":"Padagis LLC","startDate":"2019-06-24","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":495},{"nctId":"NCT04296916","phase":"NA","title":"Effect of Lowering IOP in Glaucoma Suspects With HM","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2020-04-17","conditions":"Glaucoma, Suspect, High Myopia","enrollment":264},{"nctId":"NCT00981786","phase":"PHASE4","title":"24-Hour Intraocular Pressure With Brinzolamide/Timolol Versus Brimonidine/Timolol","status":"COMPLETED","sponsor":"Aristotle University Of Thessaloniki","startDate":"2009-08","conditions":"Glaucoma","enrollment":51},{"nctId":"NCT04523844","phase":"NA","title":"Brinzolamide-brimonidine Fixed Combination for Preventing IOP Elevation After Intravitreal Anti-VEGF Injections","status":"COMPLETED","sponsor":"General Hospital of Athens Elpis","startDate":"2020-05-11","conditions":"Eye Diseases, Injection Complication, Intraocular Pressure","enrollment":47},{"nctId":"NCT02512042","phase":"PHASE3","title":"Bioequivalence Study With Clinical Endpoint Comparing Brinzolamide 1% Ophthalmic Suspension to Azopt® 1% Ophthalmic Suspension In the Treatment of Chronic Open Angle Glaucoma or Ocular Hypertension in Both Eyes","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2015-04","conditions":"Glaucoma","enrollment":973},{"nctId":"NCT01507584","phase":"NA","title":"The Effects of the Water Drinking Test on Intraocular Pressure","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2011-08","conditions":"Glaucoma","enrollment":23},{"nctId":"NCT03192826","phase":"PHASE4","title":"Brinzolamide/Brimonidine Combination vs Brimonidine 0.2% in the Prevention of IOP Rise After Nd-YAG Laser Capsulotomy","status":"COMPLETED","sponsor":"University Hospital of Patras","startDate":"2016-06-20","conditions":"Posterior Capsule Opacification, Ocular Hypertension","enrollment":79},{"nctId":"NCT03966560","phase":"PHASE4","title":"Choroidal Thickness and Its Correlations With Ocular Parameters in Primary Open-angle Glaucoma","status":"COMPLETED","sponsor":"Afyon Kocatepe University Hospital","startDate":"2014-01","conditions":"Glaucoma, Open-Angle","enrollment":96},{"nctId":"NCT02730871","phase":"PHASE4","title":"Safety and Efficacy of SIMBRINZA® BID as an Adjunctive to DUOTRAV®","status":"TERMINATED","sponsor":"Alcon Research","startDate":"2016-06-24","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":173},{"nctId":"NCT03150160","phase":"PHASE4","title":"Additive Effect of Twice-daily Brinzolamide 1%/Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-09-21","conditions":"Glaucoma","enrollment":1},{"nctId":"NCT02419508","phase":"PHASE4","title":"SIMBRINZA® Suspension BID as an Adjunctive to Prostaglandin Analogue (PGA)","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2015-08-07","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":290},{"nctId":"NCT02339584","phase":"PHASE3","title":"Efficacy and Safety of Brinzolamide/Brimonidine Fixed Combination BID Compared to Brinzolamide BID Plus Brimonidine BID in Subjects With Open-Angle Glaucoma (OAG) or Ocular Hypertension (OHT)","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2015-04-14","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":493},{"nctId":"NCT02770248","phase":"PHASE4","title":"24-hr Intraocular Pressure Control With SIMBRINZA ®","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2016-05-23","conditions":"Glaucoma","enrollment":162},{"nctId":"NCT03494257","phase":"NA","title":"Effect of Fixed Brinzolamide-brimonidine Combination on Intraocular Pressure After Phacoemulsification","status":"COMPLETED","sponsor":"University Hospital of Patras","startDate":"2017-09-04","conditions":"Cataract, Intraocular Pressure","enrollment":62},{"nctId":"NCT02331173","phase":"","title":"Clinical Evaluation of Patients With X-linked Retinoschisis","status":"COMPLETED","sponsor":"Beacon Therapeutics","startDate":"2012-11","conditions":"X-linked Retinoschisis, XLRS","enrollment":66},{"nctId":"NCT01535768","phase":"PHASE4","title":"Effect of Prophylactic Aqueous Suppression on Hyperencapsulation of Ahmed Glaucoma Valves","status":"UNKNOWN","sponsor":"Credit Valley EyeCare","startDate":"2012-02","conditions":"Glaucoma","enrollment":150},{"nctId":"NCT02325518","phase":"PHASE4","title":"Comparison of Intraocular Pressure (IOP)-Lowering Efficacy and Safety of AZORGA® Ophthalmic Suspension and COSOPT® Ophthalmic Solution","status":"COMPLETED","sponsor":"Alcon, a Novartis Company","startDate":"2014-12","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":218},{"nctId":"NCT00372827","phase":"PHASE4","title":"Study of Brinzolamide and Timolol When Added to Travoprost in Primary Open-angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2004-02","conditions":"Primary Open-angle Glaucoma, Ocular Hypertension, Pigment Dispersion Glaucoma","enrollment":245},{"nctId":"NCT00966576","phase":"PHASE4","title":"Efficacy and Safety of Adding Azarga to Prostaglandin Monotherapy","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2009-07","conditions":"Glaucoma","enrollment":47},{"nctId":"NCT01471158","phase":"PHASE4","title":"Patient Preference Comparison of AZARGA Versus COSOPT in Patients With Glaucoma","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2010-09","conditions":"Glaucoma","enrollment":120},{"nctId":"NCT00314171","phase":"PHASE3","title":"A Study of a Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2005-10","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":437},{"nctId":"NCT00326092","phase":"PHASE2","title":"A Study of a Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2006-05","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":88},{"nctId":"NCT00061516","phase":"PHASE3","title":"Safety and Efficacy Study of BETAXON 0.5% and AZOPT 1.0% in Pediatric Patients With Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2003-01","conditions":"Glaucoma, Ocular Hypertension","enrollment":78},{"nctId":"NCT00314158","phase":"PHASE3","title":"A Study of a Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2005-11","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":523},{"nctId":"NCT02165631","phase":"","title":"The Diurnal and Nocturnal Effect of Simbrinza and Timolol on Intraocular Pressure and Ocular Perfusion Pressure","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2014-08","conditions":"Open Angle Glaucoma, Ocular Hypertension, Pigment Dispersion Syndrome","enrollment":60},{"nctId":"NCT00869141","phase":"PHASE4","title":"Earlier Intraocular Pressure Control After Ahmed Glaucoma Valve Implantation for Glaucoma","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2009-03","conditions":"Glaucoma","enrollment":52},{"nctId":"NCT02140060","phase":"PHASE2","title":"6-Week Proof-of-Concept Study of Travoprost/Brinzolamide Ophthalmic Suspension in Subjects With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2014-06","conditions":"Glaucoma, Ocular Hypertension","enrollment":327},{"nctId":"NCT02348476","phase":"","title":"A Study of Simbrinza™ Therapy in Patients With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2014-11","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":150},{"nctId":"NCT01518244","phase":"PHASE4","title":"Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on Brimonidine 0.2%/Timolol 0.5% Fixed Combination Therapy (COMBIGAN®) in Latin America","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2011-12","conditions":"Glaucoma","enrollment":50},{"nctId":"NCT01111890","phase":"PHASE4","title":"Comparison of the Efficacy of AZARGA® Versus COSOPT® in Patients With Open-Angled Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2010-04","conditions":"Glaucoma, Ocular Hypertension","enrollment":70},{"nctId":"NCT01937312","phase":"PHASE4","title":"Effect of SIMBRINZA® Suspension as an Added Therapy to a Prostaglandin Analogue","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2013-10","conditions":"Ocular Hypertension, Open Angle Glaucoma","enrollment":282},{"nctId":"NCT01937299","phase":"PHASE4","title":"Effect of SIMBRINZA® Suspension as an Added Therapy to TRAVATAN Z®","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2013-10","conditions":"Ocular Hypertension, Open Angle Glaucoma","enrollment":307},{"nctId":"NCT01978600","phase":"PHASE4","title":"Evaluation of Intraocular Pressure Using Simbrinza™ in Patients With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2013-10","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":89},{"nctId":"NCT01721707","phase":"PHASE3","title":"Latanoprost/Brinzolamide BID Versus Latanoprost BID in Patients With OAG or OH","status":"WITHDRAWN","sponsor":"Adapt Produtos Oftalmológicos Ltda.","startDate":"2012-12","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":""},{"nctId":"NCT01415401","phase":"PHASE4","title":"Efficacy and Tolerability of AZARGA® as Replacement Therapy in Patients on COMBIGAN® Therapy in Canada","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2011-09","conditions":"Glaucoma, Ocular Hypertension, Open-angle Glaucoma","enrollment":57},{"nctId":"NCT01312402","phase":"PHASE4","title":"Topical Brinzolamide Ophthalmic Suspension Versus Placebo in the Treatment of Infantile Nystagmus Syndrome","status":"COMPLETED","sponsor":"Akron Children's Hospital","startDate":"2011-01","conditions":"Infantile Nystagmus Syndrome","enrollment":5},{"nctId":"NCT01263444","phase":"PHASE4","title":"Safety and Efficacy of Adding AZARGA® Adjunctive to Prostaglandin Therapy","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2011-03","conditions":"Glaucoma, Ocular Hypertension","enrollment":47},{"nctId":"NCT01357616","phase":"PHASE3","title":"Fixed Combination Brinzolamide 1%/Timolol 0.5% Versus Brinzolamide 1% + Timolol 0.5% in Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2010-11","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":328},{"nctId":"NCT01309204","phase":"PHASE3","title":"Brinzolamide/Brimonidine Twice a Day (BID) Fixed Combination (FC) vs Brinzolamide BID Plus Brimonidine BID in Patients With Open Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2011-05","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":1184},{"nctId":"NCT01310777","phase":"PHASE3","title":"Brinzolamide/Brimonidine Twice a Day (BID) Fixed Combination (FC) vs Brinzolamide BID and Brimonidine BID in Patients With Open Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2011-05","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":771},{"nctId":"NCT01340014","phase":"PHASE4","title":"Patient Preference Comparison of AZARGA Versus COSOPT","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2011-09","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":112},{"nctId":"NCT00759941","phase":"PHASE4","title":"A Comparison of Azopt Versus Placebo Added to Xalatan in Patients With Elevated Intraocular Pressure (IOP) on a Prostaglandin","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2007-10","conditions":"Glaucoma","enrollment":86},{"nctId":"NCT01514734","phase":"PHASE4","title":"Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on COMBIGAN® (Brimonidine 0.2%/Timolol 0.5% Fixed Combination) Therapy in Brazil","status":"TERMINATED","sponsor":"Alcon Research","startDate":"2012-03","conditions":"Glaucoma","enrollment":9},{"nctId":"NCT01426867","phase":"PHASE2","title":"A Comfort Study of Brinzolamide 1% / Brimonidine 0.2% Fixed Combination, Brinzolamide 1% and Brimonidine 0.2%","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2011-09","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":103},{"nctId":"NCT01297920","phase":"PHASE3","title":"Three Month Efficacy/Safety Study With a 3-Month Safety Extension of Brinzolamide 1%/Brimonidine 0.2% vs. Brinzolamide 1% or Brimonidine 0.2%","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2011-03","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":1062},{"nctId":"NCT00961649","phase":"PHASE2","title":"Safety and Efficacy of Brinzolamide/Brimonidine Fixed Combination","status":"TERMINATED","sponsor":"Alcon Research","startDate":"2009-10","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":195},{"nctId":"NCT01297517","phase":"PHASE3","title":"Efficacy and Safety Study of Brinzolamide 1%/Brimonidine 0.2% vs. Brinzolamide 1% and Brimonidine 0.2%","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2011-02","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":1001},{"nctId":"NCT01484951","phase":"PHASE4","title":"AZARGA Transition Study in Taiwan for Patients With Uncontrolled Intraocular Pressure","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2011-05","conditions":"Glaucoma","enrollment":74},{"nctId":"NCT00800540","phase":"PHASE4","title":"Circadian Ocular Perfusion Pressure and Ocular Blood Flow","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2009-02","conditions":"Glaucoma","enrollment":35},{"nctId":"NCT01055366","phase":"PHASE4","title":"ELAZOP Switching Study in Korea","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2010-03","conditions":"Open Angle Glaucoma","enrollment":96},{"nctId":"NCT00767494","phase":"PHASE3","title":"Travoprost/Brinzolamide Fixed Combination Versus Travatan and Versus AZOPT","status":"TERMINATED","sponsor":"Alcon Research","startDate":"2008-10","conditions":"Glaucoma, Ocular Hypertension","enrollment":17},{"nctId":"NCT00767481","phase":"PHASE3","title":"1 Year Study Trav/Brinz QD Fixed Combination Versus COSOPT","status":"TERMINATED","sponsor":"Alcon Research","startDate":"2008-10","conditions":"Glaucoma, Ocular Hypertension","enrollment":6},{"nctId":"NCT00761995","phase":"PHASE4","title":"Safety and Efficacy of Brinzolamide Dosed TID With Dorzolamide Dosed TID in Reducing Intraocular Pressure in Patients With Open Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2009-02","conditions":"Glaucoma, Ocular Hypertension","enrollment":200},{"nctId":"NCT00980473","phase":"PHASE3","title":"Argon Laser Peripheral Iridoplasty for Primary Angle Closure Glaucoma","status":"UNKNOWN","sponsor":"Singapore National Eye Centre","startDate":"2007-09","conditions":"Glaucoma","enrollment":80},{"nctId":"NCT01004900","phase":"PHASE3","title":"Intraocular Pressure (IOP) Lowering Effect of Selective Laser Trabeculoplasty Versus Prostaglandin Analogues in Angle Closure Glaucoma","status":"UNKNOWN","sponsor":"Singapore Eye Research Institute","startDate":"2009-06","conditions":"Glaucoma","enrollment":90},{"nctId":"NCT00471380","phase":"PHASE4","title":"A Phase IV Study of Travoprost + Brinzolamide to Treat Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2007-03","conditions":"Glaucoma, Ocular Hypertension","enrollment":46},{"nctId":"NCT00675207","phase":"PHASE4","title":"Comparison of Brimonidine Purite, Dorzolamide, and Brinzolamide as Adjunctive Therapy to Prostaglandin Analogs","status":"COMPLETED","sponsor":"Northwestern Ophthalmic Institute S.C.","startDate":"2006-01","conditions":"Primary Open Angle Glaucoma, Ocular Hypertension","enrollment":120},{"nctId":"NCT00440141","phase":"PHASE4","title":"Brimonidine 0.1% Versus Brinzolamide 1% as Adjunctive Therapy to Latanoprost 0.005%","status":"COMPLETED","sponsor":"Allergan","startDate":"2006-07","conditions":"Glaucoma, Ocular Hypertension","enrollment":40},{"nctId":"NCT00121147","phase":"NA","title":"Additivity Study: Additive Effect on Eye Pressure of Azopt and Alphagan P to Travatan","status":"COMPLETED","sponsor":"Hermann Eye Center","startDate":"2003-09","conditions":"Open Angle Glaucoma, Ocular Hypertension, Pseudoexfoliation Syndrome","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["brinzolamide"],"phase":"phase_3","status":"active","brandName":"Azopt 1%","genericName":"Azopt 1%","companyName":"Bausch & Lomb Incorporated","companyId":"bausch-lomb-incorporated","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Azopt is a topical carbonic anhydrase inhibitor that reduces intraocular pressure by decreasing aqueous humor production in the eye. Used for Glaucoma, Ocular hypertension.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}